A Bayesian re-analysis of hypothermic oxygenated perfusion versus static cold storage in the NIHP2019 heart transplantation trial.

J Heart Lung TransplantMay 25, 2026 (epub)
Clinical ResearchCardiologyCardiothoracic Surgery

Samuel Heuts, Guillaume Lebreton, Göran Dellgren et al.

✦ AI-curated · Sources linked

In 30 seconds

This Bayesian re-analysis of the NIHP2019 heart transplantation trial compared hypothermic oxygenated perfusion (HOPE) to static cold storage (SCS) in 204 patients. The study found that HOPE was associated with a lower rate of the primary composite endpoint (RR 0.71, 95%CrI 0.49-0.99; ARD -13.8%, 95%CrI -26.8; -0.4%).

Key findings

  • HOPE showed a relative risk of 0.71 for the primary composite endpoint compared to SCS.
  • The absolute risk difference for the primary endpoint was -13.8%.
  • The probability of any benefit from HOPE was 97.8%.
  • For all-cause mortality, the probability of benefit was 90.5%.

Why it matters

The findings suggest that hypothermic oxygenated perfusion may provide significant clinical benefits over static cold storage in heart transplantation, potentially influencing surgical decisions and patient outcomes.

Source

PubMed · PMID 42190853

Published in J Heart Lung Transplant. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.